David Shook Sells 1,977 Shares of Lyell Immunopharma (NASDAQ:LYEL) Stock

Lyell Immunopharma, Inc. (NASDAQ:LYEL) insider David Shook sold 1,977 shares of the company’s stock in a transaction that occurred on Wednesday, June 10th. The shares were sold at an average price of $12.64, for a total transaction of $24,989.28. Following the completion of the sale, the insider owned 20,923 shares of the company’s stock, valued at approximately $264,466.72. This trade represents a 8.63% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Lyell Immunopharma Stock Performance

Shares of NASDAQ:LYEL opened at $13.50 on Friday. The company has a market cap of $314.96 million, a PE ratio of -0.98 and a beta of -0.09. Lyell Immunopharma, Inc. has a 52 week low of $8.46 and a 52 week high of $45.00. The firm has a 50 day simple moving average of $19.17 and a 200 day simple moving average of $23.26.

Lyell Immunopharma (NASDAQ:LYEL) last issued its quarterly earnings results on Wednesday, May 6th. The company reported ($1.10) EPS for the quarter, meeting the consensus estimate of ($1.10). Lyell Immunopharma had a negative net margin of 794,858.12% and a negative return on equity of 85.71%. The business had revenue of $0.00 million during the quarter, compared to the consensus estimate of $0.00 million. On average, equities analysts predict that Lyell Immunopharma, Inc. will post -7.87 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on LYEL. Wall Street Zen upgraded shares of Lyell Immunopharma from a “sell” rating to a “hold” rating in a research report on Sunday, May 10th. HC Wainwright reiterated a “buy” rating and issued a $45.00 target price on shares of Lyell Immunopharma in a research report on Tuesday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Lyell Immunopharma in a research report on Tuesday, April 21st. Citizens Jmp began coverage on shares of Lyell Immunopharma in a research report on Monday, March 9th. They issued a “market outperform” rating and a $34.00 target price for the company. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $44.00 target price on shares of Lyell Immunopharma in a research report on Monday, June 8th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Lyell Immunopharma currently has an average rating of “Moderate Buy” and an average price target of $43.00.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of LYEL. AQR Capital Management LLC raised its holdings in shares of Lyell Immunopharma by 773.5% during the 1st quarter. AQR Capital Management LLC now owns 174,279 shares of the company’s stock valued at $94,000 after purchasing an additional 154,327 shares in the last quarter. Marshall Wace LLP bought a new position in shares of Lyell Immunopharma during the 2nd quarter valued at $94,000. Bridgeway Capital Management LLC bought a new position in shares of Lyell Immunopharma during the 2nd quarter valued at $159,000. BBR Partners LLC bought a new position in shares of Lyell Immunopharma during the 4th quarter valued at $210,000. Finally, Walleye Capital LLC bought a new position in shares of Lyell Immunopharma during the 2nd quarter valued at $258,000. Institutional investors own 66.05% of the company’s stock.

Lyell Immunopharma Company Profile

Lyell Immunopharma is a clinical-stage biotechnology company focused on developing next-generation T cell therapies for cancer. Leveraging a proprietary platform that combines cell therapy, gene editing and molecular discovery, Lyell seeks to overcome key barriers in the treatment of solid tumors. The company’s approach centers on engineering T cells to enhance their persistence, functionality and resistance to the immunosuppressive tumor microenvironment.

The company’s pipeline includes multiple autologous T cell programs engineered to target tumor-associated antigens in solid malignancies such as melanoma, ovarian and pancreatic cancers.